VECTOR DEVELOPMENT AND PRODUCTION CORE FACILITY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。载体核心指导逆转录病毒、慢病毒和重组AAV载体的生产。病毒载体生产设施通过集中生产重组病毒载体，最大限度地利用资源和提高效率，因此，所有这些都是在TNPRC进行的所有基因治疗项目中使用标准协议和相同的严格指导方针进行的。通过提供载体核心服务，VDPC将不仅对基因治疗项目产生重大影响，而且对TNPRC内的其他部门，如比较病理学、微生物学和免疫学，以及杜兰健康科学中心和路易斯安那州立大学健康科学中心的部门和中心也将产生重大影响。在与微生物学和免疫学部门的合作下，VDPC已经开始与TNPRC的研究人员一起产生表达重组蛋白的载体。核心的目标是：1。准备用于基因治疗和疫苗研究的重组病毒载体。2. 向调查人员咨询矢量设计和构造。3. 开发新型MLV， LV和AAV载体，用于未来的核心应用。4. 探索用于核心生产的新型病毒载体系统。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Vector Core directs the production of the oncoretrovirus, lentivirus, and recombinant AAV vectors. The virus vector production facility maximizes resource utilization and efficiency by centralizing the production of recombinant virus vector production, such that it is all done using standard protocols and the same strict guidelines for all of the gene therapy projects that are pursued at TNPRC. By providing vector core services, the VDPC will have a large impact not only on the Gene Therapy Program, but on other divisions such as Comparative Pathology, Microbiology and Immunology within the TNPRC, but also Departments and Centers within the Tulane Health Sciences Center and Louisiana State University Health Sciences Center. In collaboration with the Division of Microbiology and Immunology, the VDPC has begun to generate vectors that express recombinant proteins with investigators at the TNPRC. The goals of the Core are: 1. Prepare recombinant virus vectors for use in gene therapy and vaccine studies. 2. Consult with investigators on vector design and construction. 3. Develop novel MLV, LV and AAV vectors for future core use. 4. Explore novel virus vector systems for use in core production.